AA
VRTX icon

AlphaMark Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

AlphaMark Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$1.88M Buy
4,659
+7
+0.2% +$3.25K 0.81% 31
2024
Q3 		$2.16M Sell
4,652
-306
-6% -$147K 0.75% 25
2024
Q2 		$2.32M Sell
4,958
-231
-4% -$100K 0.81% 22
2024
Q1 		$2.17M Sell
5,189
-461
-8% -$195K 0.76% 23
2023
Q4 		$2.3M Sell
5,650
-130
-2% -$48K 0.87% 21
2023
Q3 		$2.01M Sell
5,780
-528
-8% -$185K 0.86% 20
2023
Q2 		$2.22M Sell
6,308
-1,600
-20% -$539K 1.02% 22
2023
Q1 		$2.49M Sell
7,908
-119
-1% -$35.7K 1.12% 20
2022
Q4 		$2.32M Sell
8,027
-291
-3% -$88.7K 1.16% 21
2022
Q3 		$2.41M Buy
8,318
+98
+1% +$28.2K 1.19% 21
2022
Q2 		$2.32M Sell
8,220
-17
-0.2% -$4.55K 1.07% 23
2022
Q1 		$2.15M Buy
8,237
+8,159
+10,460% +$1.94M 0.8% 32
2021
Q4 		$17K Buy
78
+50
+179% +$9.72K 0.01% 350
2021
Q3 		$5K Hold
28
– – ﹤0.01% 468
2021
Q2 		$6K Hold
28
– – ﹤0.01% 447
2021
Q1 		$6K Buy
28
+20
+250% +$4.39K ﹤0.01% 429
2020
Q4 		$2K Hold
8
– – ﹤0.01% 483
2020
Q3 		$2K Hold
8
– – ﹤0.01% 500
2020
Q2 		$2K Hold
8
– – ﹤0.01% 499
2020
Q1 		$2K Sell
8
-47
-85% -$10.8K ﹤0.01% 480
2019
Q4 		$12K Buy
55
+15
+38% +$3.04K 0.01% 317
2019
Q3 		$7K Sell
40
-2
-5% -$354 ﹤0.01% 370
2019
Q2 		$8K Hold
42
– – ﹤0.01% 366
2019
Q1 		$8K Hold
42
– – ﹤0.01% 354
2018
Q4 		$7K Buy
42
+32
+320% +$5.54K ﹤0.01% 354
2018
Q3 		$2K Buy
+10
New +$1.78K ﹤0.01% 475

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

AlphaMark Advisors's VRTX Position: Q4 2024 in Review

AlphaMark Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 0.15% in Q4 2024, buying an estimated $3.25K and bringing the position to 4,659 shares worth $1.88M. The position accounts for 0.81% of the portfolio, ranked #31.

AlphaMark Advisors first reported a position in VRTX in Q3 2018 and has held it in 26 quarters since. The position peaked at $2.49M in Q1 2023. 1,558 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

  • AlphaMark Advisors held 4,659 shares of Vertex Pharmaceuticals worth $1.88M as of Q4 2024.
  • AlphaMark Advisors bought 7 Vertex Pharmaceuticals shares in Q4 2024, an estimated $3.25K.
  • Vertex Pharmaceuticals made up 0.81% of AlphaMark Advisors's portfolio in Q4 2024, its #31 holding.
  • AlphaMark Advisors first reported a position in Vertex Pharmaceuticals in Q3 2018 and has held it in 26 quarters since.
  • AlphaMark Advisors's Vertex Pharmaceuticals position peaked at $2.49M in Q1 2023.
  • 1,558 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on AlphaMark Advisors's 13F filing for Q4 2024, filed 21 Jan 2025.